Electromed, Inc. (NYSE: ELMD)

Electromed, Inc., a company with the ticker symbol ELMD, operates in the healthcare industry, specifically focusing on the development, manufacturing, and marketing of innovative products that provide airway clearance therapy to patients with compromised pulmonary function.

The company's main business activities revolve around designing, manufacturing, and marketing products that provide airway clearance therapy. These products are primarily sold in the United States and select international countries, including the European Union. The company's primary product is the SmartVest Airway Clearance System, which is used to treat patients suffering from bronchiectasis, cystic fibrosis, and neuromuscular conditions such as cerebral palsy and amyotrophic lateral sclerosis (ALS).

Electromed generates revenue through the sale of its products, primarily the SmartVest System, to patients and healthcare providers in the home care and acute care settings. The SmartVest System is a programmable air pulse generator that provides high-frequency chest wall oscillation (HFCWO) therapy, which is designed to loosen and clear mucus from the lungs. The system is available in two models, the SmartVest SQL and SmartVest Clearway, which are sold into home care and hospital markets.

The company's position within the industry is strong, with a commitment to excellence and compassionate service. Electromed's products have been cleared for marketing by the US Food and Drug Administration (FDA) and are certified to apply the European Conformity (CE) marking for HFCWO device sales in all European Union member countries.

Electromed's customers include patients with compromised pulmonary function, including those with bronchiectasis, cystic fibrosis, and neuromuscular conditions such as cerebral palsy and ALS. The company's products are used in both home care and acute care settings, and it has established agreements with a limited number of Home Medical Equipment (HME) distributors to distribute and sell its products in the US home care market.

In terms of market size, Electromed estimates that the total served US market for HFCWO is approximately $250 million in 2022, growing at a 9% compound annual growth rate. The company believes that bronchiectasis is underdiagnosed and underprescribed, with an estimated 500,000 to 600,000 patients in the US who could potentially benefit from diagnosis and treatment.

Electromed's SmartVest System is a prescription-only product, which requires a physician's prescription for sale. The company markets its products to physicians and healthcare providers through visits to pulmonology clinics and medical centers, participation in medical conferences, and maintenance of industry contacts. The company also participates in industry events such as the Cystic Fibrosis Foundation World Bronchiectasis Day and American Lung Association Fight for Air Climb to increase awareness of its products and services.

Some of the company's key competitors include Baxter International Inc., Koninklijke Philips N.V., and Tactile Systems Technology Inc. These companies also participate in the HFCWO market, with Baxter and Philips employing a direct-to-patient model, while Tactile Systems Technology Inc. offers the AffloVest, which competes with Electromed's SmartVest System.

Electromed's medical devices are subject to regulation by numerous government agencies, including the FDA and comparable foreign regulatory agencies. The company is also subject to various federal and state laws that prohibit fraud and abuse in the marketing and sale of its products. Electromed maintains security protocols and processes designed to combat the risk of unauthorized access or inadvertent disclosure of customer and personnel information.

As of June 30, 2023, the company had 170 employees, an increase of 9% from fiscal 2022, who are dedicated and talented individuals, a valuable resource in accomplishing the company's collective mission and goals.